Advertisement

Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: a Review

  • Ou Yang
  • Maen Qadan
  • Marianthi IerapetritouEmail author
Review Article
  • 92 Downloads

Abstract

Purpose

There is a growing interest in continuous biopharmaceutical processing due to the advantages of small footprint, increased productivity, consistent product quality, high process flexibility and robustness, facility cost-effectiveness, and reduced capital and operating cost. To support the decision making of biopharmaceutical manufacturing, comparisons between conventional batch and continuous processing are provided.

Methods

Various process unit operations in different operating modes are summarized. Software implementation as well as computational methods used are analyzed pointing to the advantages and disadvantages that have been highlighted in the literature. Economic analysis methods and their applications in different parts of the processes are also discussed with examples from publications in the last decade.

Results

The results of the comparison between batch and continuous process operation alternatives are discussed. Possible improvements in process design and analysis are recommended. The methods used here do not reflect Lilly’s cost structures or economic evaluation methods.

Conclusion

This paper provides a review of the work that has been published in the literature on computational process design and economic analysis methods on continuous biopharmaceutical antibody production and its comparison with a conventional batch process.

Keywords

Economic analysis Batch and continuous biopharmaceutical manufacturing Antibody production Simulation software 

Notes

Funding Information

This work was supported by Eli Lilly and company.

References

  1. 1.
    Newswire PR. Monoclonal antibodies (mAbs) market analysis by source (chimeric, murine, humanized, human), by type of production, by indication (cancer, autoimmune, inflammatory, infectious, microbial, viral diseases), by end-use and segment forecasts, 2013–2024. LON-Reportbuyer: Y; 2017.Google Scholar
  2. 2.
    Gjoka X, Gantier R, Schofield M. Transfer of a three step mAb chromatography process from batch to continuous: optimizing productivity to minimize consumable requirements. J Biotechnol. 2017;242:11–8.  https://doi.org/10.1016/j.jbiotec.2016.12.005.Google Scholar
  3. 3.
    Gjoka X, Rogler K, Martino RA, Gantier R, Schofield M. A straightforward methodology for designing continuous monoclonal antibody capture multi-column chromatography processes. J Chromatogr A. 2015;1416:38–46.  https://doi.org/10.1016/j.chroma.2015.09.005.Google Scholar
  4. 4.
    Ng CKS, Rousset F, Valery E, Bracewell DG, Sorensen E. Design of high productivity sequential multi-column chromatography for antibody capture. Food Bioprod Process. 2014;92(C2):233–41.  https://doi.org/10.1016/j.fbp.2013.10.003.Google Scholar
  5. 5.
    America PRaMo. Medicines in development: biologics 2013 report. Pharmaceutical Research and Manufacturers of America. 2013. http://phrma-docs.phrma.org/sites/default/files/pdf/biologics2013.pdf. Accessed 01 June 2018.
  6. 6.
    Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. Mabs-Austin. 2015;7(1):9–14.  https://doi.org/10.4161/19420862.2015.989042.Google Scholar
  7. 7.
    Newswire PR. Monoclonal antibodies (mAbs) market Size worth $138.6 billion by 2024: grand view research, Inc. bc-Grand-View-Research: Y; 2016.Google Scholar
  8. 8.
    Gronemeyer P, Ditz R, Strube J. Trends in upstream and downstream process development for antibody manufacturing. Bioengineering. 2014;1(4):188–212.  https://doi.org/10.3390/bioengineering1040188.Google Scholar
  9. 9.
    Zydney AL. Continuous downstream processing for high value biological products: a review. Biotechnol Bioeng. 2016;113(3):465–75.Google Scholar
  10. 10.
    Whitford WG. Single-use systems support continuous bioprocessing by perfusion culture. In: Subramanian G, editor. Continuous processing in pharmaceutical manufacturing. 2014, .Google Scholar
  11. 11.
    Godawat R, Konstantinov K, Rohani M, Warikoo V. End-to-end integrated fully continuous production of recombinant monoclonal antibodies. J Biotechnol. 2015;213:13–9.  https://doi.org/10.1016/j.jbiotec.2015.06.393.Google Scholar
  12. 12.
    Taracena FL. An economic analysis for product and process design. Qual Eng. 2006;18(1):33–7.  https://doi.org/10.1080/08982110500403474.Google Scholar
  13. 13.
    Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848(1):8–18.  https://doi.org/10.1016/j.jchromb.2006.07.037.Google Scholar
  14. 14.
    Farid SS, Pollock J, Ho SV. Evaluating the economic and operational feasibility of continuous processes for monoclonal antibodies. Continuous Processing in Pharmaceutical Manufacturing. Wiley-VCH Verlag GmbH & Co. KGaA; 2014;433–56.  https://doi.org/10.1002/9783527673681.ch17.
  15. 15.
    Torres-Acosta MA, Ruiz-Ruiz F, Benavides J, Rito-Palomares M. Process economics: evaluation of the potential of ATPS as a feasible alternative to traditional fractionation techniques. Food Eng Ser. 2017;1:161–78.  https://doi.org/10.1007/978-3-319-59309-8_9.Google Scholar
  16. 16.
    Xu S, Gavin J, Jiang R, Chen H. Bioreactor productivity and media cost comparison for different intensified cell culture processes. Biotechnol Prog. 2016;33:867–78.  https://doi.org/10.1002/btpr.2415.Google Scholar
  17. 17.
    Pollock J, Coffman J, Ho SV, Farid SS. Integrated continuous bioprocessing: economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnol Prog. 2017;33:854–66.  https://doi.org/10.1002/btpr.2492.Google Scholar
  18. 18.
    Hammerschmidt N, Tscheliessnig A, Sommer R, Helk B, Jungbauer A. Economics of recombinant antibody production processes at various scales: industry-standard compared to continuous precipitation. Biotechnol J. 2014;9(6):766–75.  https://doi.org/10.1002/biot.201300480.Google Scholar
  19. 19.
    Walther J, Godawat R, Hwang C, Abe Y, Sinclair A, Konstantinov K. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. J Biotechnol. 2015;213:3–12.  https://doi.org/10.1016/j.jbiotec.2015.05.010.Google Scholar
  20. 20.
    Bunnak P, Allmendinger R, Ramasamy SV, Lettieri P, Titchener-Hooker NJ. Life-cycle and cost of goods assessment of fed-batch and perfusion-based manufacturing processes for mAbs. Biotechnol Prog. 2016;32(5):1324–35.  https://doi.org/10.1002/btpr.2323.Google Scholar
  21. 21.
    Pollock J, Ho SV, Farid SS. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty. Biotechnol Bioeng. 2013;110(1):206–19.  https://doi.org/10.1002/bit.24608.Google Scholar
  22. 22.
    Petrides D. Bioprocess design and economics. In: Roger G. Harrison PWT, Scott R. Rudge and Demetri P. Petrides, editor. Bioseparations Science and Engineering 2ed., 2015.Google Scholar
  23. 23.
    Chatterjee S, editor. FDA perspective on continuous manufacturing. IFPAC Annual Meeting; 2012; Baltimore: FDA U.S. Food and Drug Administration Protecting and Promoting Public Health.Google Scholar
  24. 24.
    Jain E, Kumar A. Upstream processes in antibody production: evaluation of critical parameters. Biotechnol Adv. 2008;26(1):46–72.  https://doi.org/10.1016/j.biotechadv.2007.09.004.Google Scholar
  25. 25.
    Novais JL, Titchener-Hooker NJ, Hoare M. Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol Bioeng. 2001;75(2):143–53.Google Scholar
  26. 26.
    Hutterer KM, Hong RW, Lull J, Zhao X, Wang T, Pei R, et al. Monoclonal antibody disulfide reduction during manufacturing: untangling process effects from product effects. Mabs-Austin. 2013;5(4):608–13.  https://doi.org/10.4161/mabs.24725.Google Scholar
  27. 27.
    Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. Mabs-Austin. 2010;2(5):480–99.Google Scholar
  28. 28.
    Jungbauer A. Continuous downstream processing of biopharmaceuticals. Trends Biotechnol. 2013;31(8):479–92.  https://doi.org/10.1016/j.tibtech.2013.05.011.Google Scholar
  29. 29.
    Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. Mabs-Austin. 2009;1(5):443–52.Google Scholar
  30. 30.
    Yang WC, Minkler DF, Kshirsagar R, Ryll T, Huang Y-M. Concentrated fed-batch cell culture increases manufacturing capacity without additional volumetric capacity. J Biotechnol. 2016;217:1–11.  https://doi.org/10.1016/j.jbiotec.2015.10.009.Google Scholar
  31. 31.
    Patil R, Walther J. Continuous manufacturing of recombinant therapeutic proteins: upstream and downstream technologies. Adv Biochem Eng Biotechnol. 2017.  https://doi.org/10.1007/10_2016_58.
  32. 32.
    Arunkumar A, Singh N, Peck M, Borys MC, Li ZJ. Investigation of single-pass tangential flow filtration (SPTFF) as an inline concentration step for cell culture harvest. J Membrane Sci. 2017;524:20–32.  https://doi.org/10.1016/j.memsci.2016.11.007.Google Scholar
  33. 33.
    Clincke MF, Molleryd C, Zhang Y, Lindskog E, Walsh K, Chotteau V. Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. effect of the cell density on the process. Biotechnol Prog. 2013;29(3):754–67.  https://doi.org/10.1002/btpr.1704.Google Scholar
  34. 34.
    Bielser JM, Wolf M, Souquet J, Broly H, Morbidelli M. Perfusion mammalian cell culture for recombinant protein manufacturing—a critical review. Biotechnol Adv. 2018;36(4):1328–40.  https://doi.org/10.1016/j.biotechadv.2018.04.011.Google Scholar
  35. 35.
    Xenopoulos A. A new, integrated, continuous purification process template for monoclonal antibodies: process modeling and cost of goods studies. J Biotechnol. 2015;213:42–53.  https://doi.org/10.1016/j.jbiotec.2015.04.020.Google Scholar
  36. 36.
    Eggersgluess JK, Richter M, Dieterle M, Strube J. Multi-stage aqueous two-phase extraction for the purification of monoclonal antibodies. Chem Eng Technol. 2014;37(4):675–82.  https://doi.org/10.1002/ceat.201300604.Google Scholar
  37. 37.
    Schmidt A, Richter M, Rudolph F, Strube J. Integration of aqueous two-phase extraction as cell harvest and capture operation in the manufacturing process of monoclonal antibodies. Antibodies. 2017;6(4):21.  https://doi.org/10.3390/antib6040021.Google Scholar
  38. 38.
    Gonzalez-Valdez J, Mayolo-Deloisa K, Rito-Palomares M. Novel aspects and future trends in the use of aqueous two-phase systems as a bioengineering tool. J Chem Technol Biot. 2018;93(7):1836–44.  https://doi.org/10.1002/jctb.5434.Google Scholar
  39. 39.
    Torres-Acosta MA, Mayolo-Deloisa K, González-Valdez J, Rito-Palomares M. Aqueous two-phase systems at large scale: challenges and opportunities. Biotechnol J. 0(0):1800117.  https://doi.org/10.1002/biot.201800117.
  40. 40.
    Godawat R, Brower K, Jain S, Konstantinov K, Riske F, Warikoo V. Periodic counter-current chromatography—design and operational considerations for integrated and continuous purification of proteins. Biotechnol J. 2012;7(12):1496–508.  https://doi.org/10.1002/biot.201200068.Google Scholar
  41. 41.
    Dutta AK, Tan J, Napadensky B, Zydney AL, Shinkazh O. Performance optimization of continuous countercurrent tangential chromatography for antibody capture. Biotechnol Prog. 2016;32(2):430–9.  https://doi.org/10.1002/btpr.2250.Google Scholar
  42. 42.
    Napadensky B, Shinkazh O, Teella A, Zydney AL. Continuous countercurrent tangential chromatography for monoclonal antibody purification. Sep Sci Technol. 2013;48(9):1289–97.  https://doi.org/10.1080/01496395.2013.767837.Google Scholar
  43. 43.
    Shinkazh O, inventor Countercurrent tangential chromatography methods, systems, and apparatus. US2011.Google Scholar
  44. 44.
    Shinkazh O, Kanani D, Barth M, Long M, Hussain D, Zydney AL. Countercurrent tangential chromatography for large-scale protein purification. Biotechnol Bioeng. 2011;108(3):582–91.  https://doi.org/10.1002/bit.22960.Google Scholar
  45. 45.
    Espitia-Saloma E, Vazquez-Villegas P, Aguilar O, Rito-Palomares M. Continuous aqueous two-phase systems devices for the recovery of biological products. Food Bioprod Process. 2014;92(C2):101–12.  https://doi.org/10.1016/j.fbp.2013.05.006.Google Scholar
  46. 46.
    Rosa PAJ, Azevedo AM, Sommerfeld S, Bäcker W, Aires-Barros MR. Continuous aqueous two-phase extraction of human antibodies using a packed column. J Chromatogr B. 2012;880(Supplement C):148–56.  https://doi.org/10.1016/j.jchromb.2011.11.034.Google Scholar
  47. 47.
    Ransohoff TC. Bisschops MAT. Google Patents: Continuous processing methods for biological products; 2013.Google Scholar
  48. 48.
    Coffman J, Goby J, Godfrey S, Orozco R, Vogel JH. Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product. Google Patents; 2017.Google Scholar
  49. 49.
    Klutz S, Lobedann M, Bramsiepe C, Schembecker G. Continuous viral inactivation at low pH value in antibody manufacturing. Chem Eng Process: Process Intensif. 2016;102(Supplement C):88–101.  https://doi.org/10.1016/j.cep.2016.01.002.Google Scholar
  50. 50.
    Orozco R, Godfrey S, Coffman J, Amarikwa L, Parker S, Hernandez L, et al. Design, construction, and optimization of a novel, modular, and scalable incubation chamber for continuous viral inactivation. Biotechnol Prog. 2017;33(4):954–65.  https://doi.org/10.1002/btpr.2442.Google Scholar
  51. 51.
    Steinebach F, Muller-Spath T, Morbidelli M. Continuous counter-current chromatography for capture and polishing steps in biopharmaceutical production. Biotechnol J. 2016;11(9):1126–41.  https://doi.org/10.1002/biot.201500354.Google Scholar
  52. 52.
    Rucker-Pezzini J, Arnold L, Hill-Byrne K, Sharp T, Avazhanskiy M, Forespring C. Single pass diafiltration integrated into a fully continuous mAb purification process. Biotechnol Bioeng. 2018;115(8):1949–57.  https://doi.org/10.1002/bit.26708.Google Scholar
  53. 53.
    Nambiar AMK, Li Y, Zydney AL. Countercurrent staged diafiltration for formulation of high value proteins. Biotechnol Bioeng. 2018;115(1):139–44.  https://doi.org/10.1002/bit.26441.Google Scholar
  54. 54.
    Kateja N, Kumar D, Sethi S, Rathore AS. Non-protein A purification platform for continuous processing of monoclonal antibody therapeutics. J Chromatogr A. 2018;1579:60–72.  https://doi.org/10.1016/j.chroma.2018.10.031.Google Scholar
  55. 55.
    Somasundaram B, Pleitt K, Shave E, Baker K, Lua LHL. Progression of continuous downstream processing of monoclonal antibodies: current trends and challenges. Biotechnol Bioeng. 2018;115:2893–907.  https://doi.org/10.1002/bit.26812.Google Scholar
  56. 56.
    Rathore AS, Kateja N, Kumar D. Process integration and control in continuous bioprocessing. Curr Opin Chem Eng. 2018;22:18–25.Google Scholar
  57. 57.
    Flickinger MC. Upstream industrial biotechnology. John Wiley & Sons.Google Scholar
  58. 58.
    Castilho LR. Continuous animal cell perfusion processes: the first step toward integrated continuous biomanufacturing. In: Subramanian G, editor. Continuous Processing in Pharmaceutical Manufacturing 2015.Google Scholar
  59. 59.
    Lee R, Mikol V, Allen E, Ruetsch N, Cameron B, Oligino T et al. Humanized anti-CXCR5 antibodies, derivatives thereof and their use. Google Patents; 2011.Google Scholar
  60. 60.
    Jozala AF, Geraldes DC, Tundisi LL, Feitosa VD, Breyer CA, Cardoso SL, et al. Biopharmaceuticals from microorganisms: from production to purification. Braz J Microbiol. 2016;47:51–63.  https://doi.org/10.1016/j.bjm.2016.10.007.Google Scholar
  61. 61.
    Pollock J, Bolton G, Coffman J, Ho SV, Bracewell DG, Farid SS. Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J Chromatogr A. 2013;1284:17–27.  https://doi.org/10.1016/j.chroma.2013.01.082.Google Scholar
  62. 62.
    Liu S, Simaria AS, Farid SS, Papageorgiou LG. Designing cost-effective biopharmaceutical facilities using mixed-integer optimization. Biotechnol Prog. 2013;29(6):1472–83.  https://doi.org/10.1002/btpr.1795.Google Scholar
  63. 63.
    Li YF, Venkatasubramanian V. Integrating design of experiments and principal component analysis to reduce downstream cost of goods in monoclonal antibody production. J Pharm Innov. 2016;11(4):352–61.  https://doi.org/10.1007/s12247-016-9263-8.Google Scholar
  64. 64.
    Klutz S, Holtmann L, Lobedann M, Schembecker G. Cost evaluation of antibody production processes in different operation modes. Chem Eng Sci. 2016;141:63–74.  https://doi.org/10.1016/j.ces.2015.10.029.Google Scholar
  65. 65.
    Torres-Acosta MA, Aguilar-Yanez JM, Rito-Palomares M, Titchener-Hooker NJ. Economic analysis of uricase production under uncertainty: contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle). Biotechnol Prog. 2016;32(1):126–33.  https://doi.org/10.1002/btpr.2200.Google Scholar
  66. 66.
    Liu S, Farid SS, Papageorgiou LG. Integrated optimization of upstream and downstream processing in biopharmaceutical manufacturing under uncertainty: a chance constrained programming approach. Ind Eng Chem Res. 2016;55(16):4599–612.  https://doi.org/10.1021/acs.iecr.5b04403.Google Scholar
  67. 67.
    Arnold L, Lee K, Rucker-Pezzini J, Lee JH. Implementation of fully integrated continuous antibody processing: effects on productivity and COGm. Biotechnol J. 2018.  https://doi.org/10.1002/biot.201800061.
  68. 68.
    Hummel J, Pagkaliwangan M, Gjoka X, Davidovits T, Stock R, Ransohoff T, et al. Modeling the downstream processing of monoclonal antibodies reveals cost advantages for continuous methods for a broad range of manufacturing scales. Biotechnol J. 2018.  https://doi.org/10.1002/biot.201700665.
  69. 69.
    Grilo AL, Mateus M, Aires-Barros MR, Azevedo AM. Monoclonal antibodies production platforms: an opportunity study of a non-protein-A chromatographic platform based on process economics. Biotechnol J. 2017;12(12).  https://doi.org/10.1002/biot.201700260.
  70. 70.
    The biopharmaceutical industry’s leading process analysis and economic modelling package. In: BioSolve Process 7. Biopharm. 2016. https://biopharmservices.com/wp-content/uploads/2016/02/Process-2pp-A4-2016-2-FINAL.pdf. Accessed 8/9 2017.
  71. 71.
    Aspentech. Aspen Batch Process Developer https://www.aspentech.com/en/products/pages/aspen-batch-process-developer. Accessed 12/19 2018.
  72. 72.
    Aspentech. Aspen Chromatogrpahy. https://www.aspentech.com/en/products/pages/aspen-chromatography. Accessed 12/19 2018.
  73. 73.
    Ashouri P. A dynamic simulation framework for biopharmaceutical capacity management: University College London; 2011.Google Scholar
  74. 74.
    Sachidananda M, Erkoyuncu J, Steenstra D, Michalska S. Discrete event simulation modelling for dynamic decision making in biopharmaceutical manufacturing. Procedia CIRP. 2016;49:39–44.  https://doi.org/10.1016/j.procir.2015.07.026.Google Scholar
  75. 75.
    Towler G, Sinnott RK. Chemical engineering design: principles, practice and economics of plant and process design: Elsevier; 2012.Google Scholar
  76. 76.
    Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018;24(2):109–+.Google Scholar
  77. 77.
    Pannell DJ. Sensitivity analysis: strategies, methods, concepts, examples. Agric Econ. 1997;16:139–52.Google Scholar
  78. 78.
    Torres-Acosta MA, Aguilar-Yanez JM, Rito-Palomares M, Titchener-Hooker NJ. Economic analysis of Royalactin production under uncertainty: evaluating the effect of parameter optimization. Biotechnol Prog. 2015;31(3):744–9.  https://doi.org/10.1002/btpr.2073.Google Scholar
  79. 79.
    Vermasvuori R, Hurme M. Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes. Biotechnol Prog. 2011;27(6):1588–98.  https://doi.org/10.1002/btpr.676.Google Scholar
  80. 80.
    Repligen inspiring advances in bioprocessing. Frequently asked questions—perfusion. Repligen inspiring advances in bioprocessing official web-site. 2017. https://www.repligen.com/products/upstream-solutions/xcell-atf-cell-retention-system/faq-perfusion/#steady. Accessed 1 June 2018.
  81. 81.
    Konstantinov KB, Cooney CL. White paper on continuous bioprocessing. May 20–21, 2014 continuous manufacturing symposium. J Pharm Sci. 2015;104(3):813–20.  https://doi.org/10.1002/jps.24268.Google Scholar
  82. 82.
    Roque ACA, Lowe CR, Taipa MÂ. Antibodies and genetically engineered related molecules: production and purification. Biotechnol Prog. 2004;20(3):639–54.Google Scholar
  83. 83.
    Azevedo AM, Rosa PAJ, Ferreira IF, Aires-Barros MR. Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. Trends Biotechnol. 2009;27(4):240–7.  https://doi.org/10.1016/j.tibtech.2009.01.004.Google Scholar
  84. 84.
    Farid SS. Economic drivers and trade-offs in antibody purification processes. BioPharm International. 2009; 2009(7).Google Scholar
  85. 85.
    Karst DJ, Serra E, Villiger TK, Soos M, Morbidelli M. Characterization and comparison of ATF and TFF in stirred bioreactors for continuous mammalian cell culture processes. Biochem Eng J. 2016;110:17–26.  https://doi.org/10.1016/j.bej.2016.02.003.Google Scholar
  86. 86.
    Espitia-Saloma E, Vazquez-Villegas P, Rito-Palomares M, Aguilar O. An integrated practical implementation of continuous aqueous two-phase systems for the recovery of human IgG: from the microdevice to a multistage bench-scale mixer-settler device. Biotechnol J. 2016;11(5):708–16.  https://doi.org/10.1002/biot.201400565.Google Scholar
  87. 87.
    Angarita M, Muller-Spath T, Baur D, Lievrouw R, Lissens G, Morbidelli M. Twin-column CaptureSMB: a novel cyclic process for protein A affinity chromatography. J Chromatogr A. 2015;1389:85–95.  https://doi.org/10.1016/j.chroma.2015.02.046.Google Scholar
  88. 88.
    Varadaraju H, Schneiderman S, Zhang L, Fong H, Menkhaus TJ. Process and economic evaluation for monoclonal antibody purification using a membrane-only process. Biotechnol Prog. 2011;27(5):1297–305.  https://doi.org/10.1002/btpr.639.Google Scholar
  89. 89.
    Liu SS, Papageorgiou LG. Multi-objective optimisation for biopharmaceutical manufacturing under uncertainty. Comput Chem Eng. 2018;119:383–93.  https://doi.org/10.1016/j.compchemeng.2018.09.015.Google Scholar
  90. 90.
    Popova D, Stonier A, Pain D, Titchener-Hooker NJ, Farid SS. Integrated economic and experimental framework for screening of primary recovery technologies for high cell density CHO cultures. Biotechnol J. 2016;11(7):899–909.  https://doi.org/10.1002/biot.201500336.Google Scholar
  91. 91.
    Torres-Acosta MA, Pereira JFB, Freire MG, Aguilar-Yanez JM, Coutinho JAP, Titchener-Hooker NJ, et al. Economic evaluation of the primary recovery of tetracycline with traditional and novel aqueous two-phase systems. Sep Purif Technol. 2018;203:178–84.  https://doi.org/10.1016/j.seppur.2018.04.041.Google Scholar
  92. 92.
    Lopes AG. Single-use in the biopharmaceutical industry: a review of current technology impact, challenges and limitations. Food Bioprod Process. 2015;93:98–114.  https://doi.org/10.1016/j.fbp.2013.12.002.Google Scholar
  93. 93.
    Berthold Boedeker JM. Opportunities and limitations of continuous processing and use of disposables. Am Pharm Rev. 2017.Google Scholar
  94. 94.
    Shukla AA, Gottschalk U. Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 2013;31(3):147–54.  https://doi.org/10.1016/j.tibtech.2012.10.004.Google Scholar
  95. 95.
    Langer ES, Rader RA. Single-use technologies in biopharmaceutical manufacturing: a 10-year review of trends and the future. Engineering in Life Sciences. 2014;14(3):238–43.  https://doi.org/10.1002/elsc.201300090.Google Scholar
  96. 96.
    Marc Bisschops LF, Scott Fulton, Tom Ransohoff. Single-use, continuous-countercurrent, multicolumn chromatography. BioProcess International. 2009.Google Scholar
  97. 97.
    Michael LaBreck MP. An economic analysis of single—use tangential flow filtration for biopharmaceutical applications. BioProcess International. 2010;2010 Supplement(8).Google Scholar
  98. 98.
    Jacquemart R, Vandersluis M, Zhao MC, Sukhija K, Sidhu N, Stout J. A single-use strategy to enable manufacturing of affordable biologics. Comput Struct Biotec. 2016;14:309–18.  https://doi.org/10.1016/j.csbj.2016.06.007.Google Scholar
  99. 99.
    Shirahata H, Hirao M, Sugiyama H. Decision-support method for the choice between single-use and multi-use technologies in sterile drug product manufacturing. J Pharm Innov. 2017;12(1):1–13.  https://doi.org/10.1007/s12247-016-9264-7.Google Scholar
  100. 100.
    Magnus J, Temming M, Schwan P, Micovic J, Lobedam M, Sievers S, editors. A biomanufacturing facility based on continuous processing and single use technology2015.Google Scholar
  101. 101.
    Yang WC, Lu J, Kwiatkowski C, Yuan H, Kshirsagar R, Ryll T, et al. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality. Biotechnol Prog. 2014;30(3):616–25.  https://doi.org/10.1002/btpr.1884.Google Scholar
  102. 102.
    Farid SS. Established bioprocesses for producing antibodies as a basis for future planning. In: Hu W-S, editor. Cell Culture Engineering. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006. p. 1–42.Google Scholar
  103. 103.
    Rathore AS, Agarwal H, Sharma AK, Pathak M, Muthukumar S. Continuous processing for production of biopharmaceuticals. Prep Biochem Biotechnol. 2015;45(8):836–49.  https://doi.org/10.1080/10826068.2014.985834.Google Scholar
  104. 104.
    St Amand MM, Hayes J, Radhakrishnan D, Fernandez J, Meyer B, Robinson AS, et al. Identifying a robust design space for glycosylation during monoclonal antibody production. Biotechnol Prog. 2016;32(5):1149–62.  https://doi.org/10.1002/btpr.2316.Google Scholar
  105. 105.
    Radhakrishnan D, Robinson AS, Ogunnaike BA. Controlling the glycosylation profile in mAbs using time-dependent media supplementation. Antibodies. 2018;7(1):1.  https://doi.org/10.3390/antib7010001.Google Scholar
  106. 106.
    Ogonah OW, Polizzi KM, Bracewell DG. Cell free protein synthesis: a viable option for stratified medicines manufacturing? Curr Opin Chem Eng. 2017;18:77–83.  https://doi.org/10.1016/j.coche.2017.10.003.Google Scholar
  107. 107.
    Stech M, Kubick S. Cell-free synthesis meets antibody production: a review. Antibodies. 2015;4(1):12–33.  https://doi.org/10.3390/antib4010012.Google Scholar
  108. 108.
    Martin RW, Majewska NI, Chen CX, Albanetti TE, Jimenez RBC, Schmelzer AE, et al. Development of a CHO-based cell-free platform for synthesis of active monoclonal antibodies. ACS Synth Biol. 2017;6(7):1370–9.  https://doi.org/10.1021/acssynbio.7b00001.Google Scholar
  109. 109.
    Shirokov VA, Simonenko PN, Biryukov SV, Spirin AS. Continuous-flow and continuous-exchange cell-free translation systems and reactors. In: Spirin AS, editor. Cell-free translation systems. Berlin, Heidelberg: Springer Berlin Heidelberg; 2002. p. 91–107.Google Scholar
  110. 110.
    Stech M, Nikolaeva O, Thoring L, Stocklein WFM, Wustenhagen DA, Hust M, et al. Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates. Sci Rep-Uk. 2017;7:12030.  https://doi.org/10.1038/s41598-017-12364-w.Google Scholar
  111. 111.
    Dutta AK, Tran T, Napadensky B, Teella A, Brookhart G, Ropp PA, et al. Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography. J Biotechnol. 2015;213:54–64.  https://doi.org/10.1016/j.jbiotec.2015.02.026.Google Scholar
  112. 112.
    Dutta AK, Fedorenko D, Tan J, Costanzo JA, Kahn DS, Zydney AL, et al. Continuous countercurrent tangential chromatography for mixed mode post-capture operations in monoclonal antibody purification. J Chromatogr A. 2017;1511:37–44.  https://doi.org/10.1016/j.chroma.2017.06.018.Google Scholar
  113. 113.
    Rosa PA, Azevedo AM, Sommerfeld S, Mutter M, Backer W, Aires-Barros MR. Continuous purification of antibodies from cell culture supernatant with aqueous two-phase systems: from concept to process. Biotechnol J. 2013;8(3):352–62.  https://doi.org/10.1002/biot.201200031.Google Scholar
  114. 114.
    Rosa PAJ, Azevedo AM, Sommerfeld S, Bäcker W, Aires-Barros MR. Aqueous two-phase extraction as a platform in the biomanufacturing industry: economical and environmental sustainability. Biotechnol Adv. 2011;29(6):559–67.  https://doi.org/10.1016/j.biotechadv.2011.03.006.Google Scholar
  115. 115.
    Rosa PAJ, Ferreira IF, Azevedo AM, Aires-Barros MR. Aqueous two-phase systems: a viable platform in the manufacturing of biopharmaceuticals. J Chromatogr A. 2010;1217(16):2296–305.  https://doi.org/10.1016/j.chroma.2009.11.034.Google Scholar
  116. 116.
    Fisher AC, Kamga MH, Agarabi C, Brorson K, Lee SL, Yoon S. The current scientific and regulatory landscape in advancing integrated continuous biopharmaceutical manufacturing. Trends Biotechnol. 2018.  https://doi.org/10.1016/j.tibtech.2018.08.008.
  117. 117.
    Fisher AC, Lee SL, Harris DP, Buhse L, Kozlowski S, Yu L, et al. Advancing pharmaceutical quality: an overview of science and research in the U.S. FDA’s Office of Pharmaceutical Quality. Int J Pharm. 2016;515(1–2):390–402.  https://doi.org/10.1016/j.ijpharm.2016.10.038.Google Scholar
  118. 118.
    Raftery JP, DeSessa MR, Karim MN. Economic improvement of continuous pharmaceutical production via the optimal control of a multifeed bioreactor. Biotechnol Prog. 2017;33(4):902–12.  https://doi.org/10.1002/btpr.2433.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Chemical and Biochemical EngineeringRutgers—The State University of New JerseyPiscatawayUSA
  2. 2.Eli Lilly and CompanyIndianapolisUSA

Personalised recommendations